Skip to main content
Fig. 2 | Cellular & Molecular Biology Letters

Fig. 2

From: Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease

Fig. 2

Relationship between MAFLD and the GPR119/incretin axis. When GPR119 is activated by different ligands, it leads to an increase in cAMP and combines with PKA to secrete incretins. After further activating the corresponding receptor, it can improve the disease characteristics in MAFLD through the ERK1/2 signaling pathway. AC, adenylyl cyclase. cAMP, cyclic AMP. PKA, protein kinase A. ERK1/2, extracellular signal-regulated protein kinase 1 and 2

Back to article page

Cellular & Molecular Biology Letters

ISSN: 1689-1392

Contact us